Literature DB >> 2794549

Chronic cyclosporine-induced autoimmune disease in the rat: a new experimental model for scleroderma.

G M Bos1, G D Majoor, R G Willighagen, P J van Breda Vriesman.   

Abstract

The pathogenesis of scleroderma is still elusive, although autoimmune mechanism involvement has been suggested. The present study was designed to investigate whether or not rat scleroderma would appear as one of the symptoms in a recently described model for autoimmune disease. The model is based on manipulation or reconstitution of the immune system after lethal irradiation and syngeneic bone marrow transplantation by temporary administration of the immunosuppressive drug cyclosporine-A. Withdrawal of cyclosporine-A 6-12 wk after bone marrow transplantation gives rise to autoimmune reactions causing clinical pathology similar to graft-versus-host disease. We discuss the chronic phase of this disease, approximately 30 wk after cyclosporine-A was withheld at that time-about one-third of the rats had developed histologic skin lesions comparable to those seen in patients with scleroderma. Therefore, we propose this model as a new, experimental autoimmune model for scleroderma in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794549     DOI: 10.1111/1523-1747.ep12319732

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

Review 1.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

2.  A dominant role for non-MHC gene effects in susceptibility to cyclosporin A (CsA)-induced autoimmunity.

Authors:  J G Damoiseaux; L J Beijleveld; P J van Breda Vriesman
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

3.  Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal.

Authors:  P Casoli; C Carretti; B Tumiati
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.